{"Clinical Trial ID": "NCT00393939", "Intervention": ["INTERVENTION 1:", "Docetaxel + Sunitinib", "\u2022 Sunitinib 37.5 milligrams (mg) per day per oral capsule for 2 weeks followed by a one-week discontinuation period (Appendix 2/1) with docetaxel 75 milligrams per square metre (mg/m^2) every 3 weeks, or sunitinib 37.5 mg per day under continuous administration (in the absence of docetaxel), or docetaxel 100 mg/m^2 every 3 weeks (in the absence of sunitinib).", "INTERVENTION 2:", "Docetaxel", "Docetaxel 100 mg/m^2 every 3 weeks"], "Eligibility": ["Incorporation criteria:", "\u2022 Breast cancer with signs of recurrent local resecability or metastatic disease", "2 negative tumours", "- Exclusion criteria:", "Patients for whom docetaxel is contraindicated", "Clinical presentation of inflammatory carcinoma without other measurable disease"], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "The PSF is defined as the time from the date of randomization to the date of the first documentation on the progression or objective death of the tumour due to any cause, depending on the first of these causes. The PSF is calculated as (month) = (date of first event minus date of randomization plus 1) divided by 30.4.", "Time limit: Baseline data up to month 33", "Results 1:", "Title of the arm/group: Docetaxel + Sunitinib", "Description of the arm/group: Sunitinib 37.5 milligrams (mg) per day per oral capsule for 2 weeks followed by a one-week discontinuation period (Appendix 2/1) with docetaxel 75 milligrams per square metre (mg/m^2) every 3 weeks, or sunitinib 37.5 mg per day under continuous administration (in the absence of docetaxel), or docetaxel 100 mg/m^2 every 3 weeks (in the absence of sunitinib).", "Total number of participants analysed: 296", "Median (95% confidence interval)", "Unit of measure: month Independent radiology assessment: 8.6 (8.2-10.3)", "The investigator's assessment: 8.2 (7.3 to 8.6)", "Results 2:", "Title of the arm/group : Docetaxel", "Description of the arm/group: Docetaxel 100 mg/m^2 every 3 weeks", "Total number of participants analysed: 297", "Median (95% confidence interval)", "Unit of measure: month Independent radiology assessment: 8.3 (7.7 to 9.6)", "\u25cf Investigator's assessment: 6.9 (6.5 to 7.3)"], "Adverse Events": ["Undesirable Events 1:", "Total: 112/295 (37.97 per cent)", "Anemia 4/295 (1.36%)", "Febrile neutropenia 20/295 (6.78%)", "Leukopenia 5/295 (1.69%)", "Lymphatic disorders 1/295 (0.34%)", "Neutropenia 11/295 (3.73%)", "Thrombocytopenia 1/295 (0.34%)", "Angine pectoris 0/295 (0.00 %)", "Atrial fibrillation 1/295 (0.34%)", "Atrioventricular block 1/295 (0.34%)", "Cardiac arrest 1/295 (0.34%)", "Cardiac disorders 1/295 (0.34%)", "Adverse Events 2:", "Total: 79/293 (26.96 per cent)", "Anemia 2/293 (0.68%)", "13/293 (4.44 per cent)", "\u00b7 Leucopenia 7/293 (2.39 per cent)", "- Lymphatic disorder 0/293 (0.00 %)", "Neutropenia 16/293 (5.46%)", "Thrombocytopenia 0/293 (0.00 %)", "Angina pectoris 1/293 (0.34%)", "Atrial fibrillation 0/293 (0.00 %)", "Atrioventricular block 0/293 (0.00 %)", "Cardiac arrest 0/293 (0.00 %)", "Cardiac disorder 0/293 (0.00 %)"]}